<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2026.1753321</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>lncRNA-based prognostic model for pancreatic cancer centered on the TME with exploratory LLPS connections</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Wei</surname><given-names>Yaqing</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3292364/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Sun</surname><given-names>Xiguang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Ding</surname><given-names>Changjun</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Yifei</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Lu</surname><given-names>Zheran</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Chenhui</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Yao</surname><given-names>Hao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huang</surname><given-names>Hao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1884818/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Hepatopancreatobiliary Surgery, The Second Hospital of Tianjin Medical University</institution>, <city>Tianjin</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Tianjin Medical University</institution>, <city>Tianjin</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>RWTH Aachen University</institution>, <city>Aachen</city>, <state>North Rhine-Westphalia</state>,&#xa0;<country country="de">Germany</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Hao Huang, <email xlink:href="mailto:huangh1203@tmu.edu.cn">huangh1203@tmu.edu.cn</email></corresp>
<fn fn-type="equal" id="fn003">
<label>&#x2020;</label>
<p>These authors have contributed equally to this work and share first authorship</p></fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-23">
<day>23</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>16</volume>
<elocation-id>1753321</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>27</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Wei, Sun, Ding, Wang, Lu, Zhang, Yao and Huang.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Wei, Sun, Ding, Wang, Lu, Zhang, Yao and Huang</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-23">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Liquid-Liquid Phase Separation (LLPS), tumor microenvironment (TME), and long non-coding RNA (lncRNA) all have varying degrees of influence on the expression regulation of tumors. However, research on the association of these three in pancreatic cancer (PC) still requires further exploration. This study seeks to establish the relationships among these three themes through bioinformatics and to identify biomarkers that can predict the prognosis of PC patients.</p>
</sec>
<sec>
<title>Methods</title>
<p>Data sets from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) are obtained from the UCSC platform. lncRNAs associated with the LLPS and TME gene sets are screened, and model lncRNAs are identified through comprehensive analysis conducted with least absolute shrinkage and selection operator (LASSO) regression and cox proportional hazards (COX) regression. Additionally, the predictive efficacy of the model lncRNAs is validated through multiple databases and cohorts. Furthermore, the expression of the model lncRNAs is validated at a biological level.</p>
</sec>
<sec>
<title>Results</title>
<p>A comprehensive analysis establishes an optimal combination consisting of 5 lncRNAs. The Kaplan&#x2013;Meier curves and receiver operating characteristic (ROC) curves for each cohort demonstrates the effectiveness of the model lncRNAs characteristics. Additionally, the COX regression analysis of clinical characteristics and the analysis of mutation data further indicates the stability of the model lncRNAs. Furthermore, the expression levels of model lncRNAs in cell lines are consistent with the analysis results.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The model lncRNAs identified in this study, which are correlated with LLPS and TME, demonstrate significant potential as independent biomarkers for predicting the prognosis of PC patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>LLPS</kwd>
<kwd>LncRNA - long noncoding RNA</kwd>
<kwd>pancreatic cancer</kwd>
<kwd>prognosis</kwd>
<kwd>TME (tumor microenvironment)</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the 2023 Youth Incubation Fund of The Second Hospital of Tianjin Medical University (Number: 2023ydey07).</funding-statement>
</funding-group>
<counts>
<fig-count count="9"/>
<table-count count="1"/>
<equation-count count="1"/>
<ref-count count="41"/>
<page-count count="13"/>
<word-count count="4497"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>PC has been increasing in both incidence and mortality rates each year. It has been reported that PC ranks 12th in incidence among all cancers and 6th in cumulative mortality rates (<xref ref-type="bibr" rid="B1">1</xref>). It is project that by 2030, PC will become the second leading cause of cancer-related deaths in the United States (<xref ref-type="bibr" rid="B2">2</xref>). Studies indicate that the lifetime risk of developing PC worldwide is up to 0.89% (95%CI: 0.88&#x2013;0.89), and the median overall survival (OS) among all stages of the disease is only 4 months (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>). This severe treatment burden imposes a heavy burden on socioeconomic development, making it urgent to explore potential prognostic biomarkers to guide treatment for PC.</p>
<p>Previous studies have shown that the assessment of clinical risk factors for PC prognosis is unsatisfactory. Known risk factors do not sufficiently explain the development of PC (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). However, in recent years, lncRNA has garnered widespread attention in oncology research (<xref ref-type="bibr" rid="B8">8</xref>). lncRNA influences tumor occurrence and progression through various mechanisms, including gene expression, post-transcriptional regulation, and cell proliferation (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Particularly in PC, abnormal expression of lncRNA is closely associated with tumor aggressiveness, metastasis, and prognosis (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Additionally, the characteristics of the PC microenvironment are distinct, including hypoxia and high fibrosis (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). lncRNA participates in the construction of this network by regulating immune cells and cancer-associated fibroblasts within the TME (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Notably, lncRNA can also influence the expression of the TME by regulating the extracellular matrix, metabolic status, and intercellular signaling (<xref ref-type="bibr" rid="B17">17</xref>).</p>
<p>It is worth noting that the close relationship between lncRNA and LLPS during tumor progression is one of the important factors affecting the TME (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). lncRNA can form condensates in the nucleus through LLPS, and these condensates not only participate in the regulation of gene transcription but may also act as signal integrators to respond to changes in the microenvironment (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Normal biomolecular condensates ensure fundamental cellular functions, while their anomalous forms can lead to cellular dysfunction and potential tumor (<xref ref-type="bibr" rid="B22">22</xref>). Studies have demonstrated that LLPS plays a crucial role in regulating tumor proliferation and metastasis (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). A significant number of lncRNAs are localized on chromatin and often form RNA-clouds within specific nuclear regions to regulate gene expression. As major components of various membraneless structures, such as nucleolus and paraspeckles, lncRNAs are frequently imbalanced in cancer (<xref ref-type="bibr" rid="B25">25</xref>). Recent research has shown that certain lncRNA subdomains can selectively combine to proteins like NONO/SFPQ, which dynamically oligomerize and recruit additional proteins through LLPS (<xref ref-type="bibr" rid="B26">26</xref>). This process not only participates in gene expression regulation, RNA processing, and cellular stress responses but is also highly sensitive to cellular states and environmental signals (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). In summary, this study will anchor biomarkers at the mechanistic level of tumors, screening lncRNA based on the LLPS and TME gene sets to give a reference for the prognosis of PC.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2_1">
<title>Data acquisition and integration</title>
<p>The data included in this study originates from the TCGA and ICGC datasets on the UCSC platform. 165 tumor samples and 171 normal tissue samples originate from the GTEx-TCGA dataset. This dataset is employed for model construction and serves as an internal validation dataset. To enhance the stability of the model, Researchers also include 90 pancreatic tumor samples sourced from the ICGC dataset, which serve as an external validation dataset. Additionally, differential expression analysis of the GTEx-TCGA gene matrix is conducted with the R language software version 4.2.3 (log<sub>2</sub>FC &gt; 1.0, FDR&lt; 0.05, <italic>P-</italic>value&lt; 0.05). Overall, a total of 5, 901 genes and 200 lncRNAs are identified as significantly differentially expressed.</p>
</sec>
<sec id="s2_2">
<title>Confirm the theme-related target gene and potential lncRNA</title>
<p>Based on the GeneCards search engine, gene sets are retrieved with the keywords &#x2018;TME&#x2019; and &#x2018;LLPS&#x2019;. Following this, the intersection of these two gene sets is constructed. This intersected gene set is then combined with the 5, 901 differentially expressed genes to identify those that are associated with both themes. Subsequently, the limma R package is applied to perform a correlation analysis between the identified lncRNAs and the intersected genes. As a result, 138 lncRNAs that are linked to both &#x2018;TME&#x2019; and &#x2018;LLPS&#x2019; are confirmed as potential lncRNAs for further analysis.</p>
</sec>
<sec id="s2_3">
<title>Model construction and cohort grouping</title>
<p>To test the effectiveness of the model lncRNA, 165 tumor samples from the GTEx-TCGA dataset are randomly divided into two independent cohorts: a training cohort and a validation cohort. The optimal model is constructed with COX regression, and LASSO regression. To assess the performance of the model lncRNA and reduce the risk of overfitting, 10-fold cross-validation is conducted along with 1, 000 random perturbations applied to the training cohort. The formula is then applied to calculate the risk score, where lncRNA<sup>k</sup>= coef(lncRNA<sup>k</sup>)&#xd7; expr(lncRNA<sup>k</sup>), with &#x201c;coef&#x201d; representing the survival coefficient and &#x201c;expr&#x201d; indicating the gene expression level. Based on the median risk score, both the training and validation cohort, as well as the external validation dataset, are all classified into low-risk and high-risk subgroups for further analysis.</p>
<disp-formula>
<mml:math display="block" id="M1"><mml:mrow><mml:mtext>risk</mml:mtext><mml:mo>&#xa0;</mml:mo><mml:mtext>score</mml:mtext><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mtext>k</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mtext>n</mml:mtext></mml:munderover><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>lncRN</mml:mtext><mml:msup><mml:mtext>A</mml:mtext><mml:mtext>k</mml:mtext></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mstyle><mml:mo>&#xa0;</mml:mo></mml:mrow></mml:math>
</disp-formula>
</sec>
<sec id="s2_4">
<title>Assess the survival prediction efficacy of model lncRNA</title>
<p>The researchers conduct internal validation by comparing survival status and survival curves of risk subgroups within the training and validation cohorts. To further evaluate the predictive efficacy of model lncRNA in the internal dataset, time-dependent ROC curves and clinical characteristics ROC curves are employed. Building on this evaluation, survival analyses and time-dependent ROC curves for the risk subgroups are performed on the entire TCGA dataset. These analyses are also conducted in an external dataset to illustrate the efficacy of the model lncRNA. Furthermore, researchers compare survival differences in clinical characteristics, such as age, gender, tumor grade, and tumor stage, between low-risk and high-risk subgroups. Finally, the reliability of risk scores is confirmed through the construction of univariate and multivariate COX regression analysis, which develops the predictive capability of the model lncRNA.</p>
</sec>
<sec id="s2_5">
<title>Construction of mutation data analysis</title>
<p>To further illustrate the efficacy of the model lncRNA, this study extracts mutation data from samples in the TCGA database. Researchers perform correlation analyses to reveal differences in mutation data between the low-risk and high-risk subgroups. Following this, the study categorizes the samples into two groups based on the median tumor mutation burden (TMB) coefficient: low-TMB (L-TMB) and high-TMB (H-TMB). Subsequently, researchers construct survival analysis curves for the mutation subgroups. Finally, researchers correlate the mutation subgroups with the risk subgroups to conduct survival analysis. This analysis strengthens the evidence for the model lncRNAs effectiveness and stability.</p>
</sec>
<sec id="s2_6">
<title>Model lncRNAs expression validation in cell lines</title>
<p>In this study, four cell lines&#x2014;hTERT-HPNE (HPDE), PANC-1, ASPC-1, and MIA-PACA-2&#x2014;are selected for qPCR experiments. The primer and housekeeping gene sequences applied in the research can be found in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 9</bold></xref>. Each gene is conducted in triplicate and repeated three times in different cell lines. The results are averaged, and the standard deviation is calculated to assess variability. Relative expression is quantified using the 2<sup>-&#x394;&#x394;CT</sup> method, and statistical analysis is performed with a t-test. Finally, the results are visualized with Prism software version 9.5.1.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Selection of target gene and model lncRNA</title>
<p>The research flowchart for this study is shown in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>. Through the analysis of sample data from the GTEx-TCGA dataset, researchers discover 3469 genes that are differentially expressed (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 1</bold></xref>). We subsequently obtained 727 theme genes from the GeneCards website (version 5.24) with gifts score greater than 10 and a relevance score greater than 0.30 (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 2</bold></xref>). After intersecting the differentially expressed genes with the theme genes, researchers discover 72 target genes (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2A</bold></xref>). From the correlation analysis results, researchers discover 138 lncRNAs linked to target genes, prompting the development of a heatmap showing the top 30 lncRNAs (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2B</bold></xref>; <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 3</bold></xref>). The training and validation cohorts are validated as independent datasets based on the chi-square method (<xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>). Analyzing the sample data from the training cohort, researchers initially identify 7 lncRNAs through univariate COX regression analysis (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2C</bold></xref>). To validate the result, researchers subsequently perform LASSO analysis, conducting 1, 000 random cycles (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2D, E</bold></xref>). Finally, through multivariate COX regression analysis, 5 lncRNAs are selected as model lncRNAs (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3A</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Research flowchart. The arrows indicate the steps of research progress.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g001.tif">
<alt-text content-type="machine-generated">Flowchart depicting the development and validation of a 5-lnRNAs predictive model. It begins with gene screening, identifying 3,470 eligible genes. Through selection criteria, differentially expressed lncRNAs related to LLPS and TME are identified. After regression analysis, a model is constructed using TCGA train cohort data. Validation is done using ICGC and TCGA cohorts. The model undergoes bioinformatics and biological validations, followed by analyses of survival prognosis, clinical characteristics, and tumor mutation burden.</alt-text>
</graphic></fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Identification of target genes and lncRNAs. <bold>(A)</bold> Volcano plot of 72 target genes. <bold>(B)</bold> Heatmap of the top 30 target genes with the highest correlation from the correlation analysis results. <bold>(C)</bold> Seven potential signature lncRNAs selected through univariate COX regression. <bold>(D)</bold> Coefficient path diagram from LASSO regression. <bold>(E)</bold> Likelihood ratio test plot for the model from LASSO regression.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g002.tif">
<alt-text content-type="machine-generated">Panel A shows a scatter plot of gene expression changes between groups, with upregulated genes in pink and downregulated in blue. Panel B displays a heatmap comparing gene expression in tumor and normal tissue. Panel C presents a forest plot of hazard ratios and p-values for various genes, displaying confidence intervals. Panel D is a line plot illustrating coefficients against log lambda values in LASSO regression. Panel E shows cross-validation results for selecting lambda in LASSO regression, highlighting the optimal lambda with a red line.</alt-text>
</graphic></fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Basic information of the random cohort.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Clinical indicators</th>
<th valign="middle" align="left">Classification</th>
<th valign="middle" align="left">Total</th>
<th valign="middle" align="left">Validation</th>
<th valign="middle" align="left">Training</th>
<th valign="middle" align="left"><italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Age (Year)</td>
<td valign="middle" align="left">&lt;=65</td>
<td valign="middle" align="left">84</td>
<td valign="middle" align="left">41(51.25%)</td>
<td valign="middle" align="left">43(53.09%)</td>
<td valign="middle" align="left">0.9399</td>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">&gt;65</td>
<td valign="middle" align="left">77</td>
<td valign="middle" align="left">39(48.75%)</td>
<td valign="middle" align="left">38(46.91%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Gender</td>
<td valign="middle" align="left">Female</td>
<td valign="middle" align="left">74</td>
<td valign="middle" align="left">36(45.00%)</td>
<td valign="middle" align="left">38(46.91%)</td>
<td valign="middle" align="left">0.9319</td>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">Male</td>
<td valign="middle" align="left">87</td>
<td valign="middle" align="left">44(55.00%)</td>
<td valign="middle" align="left">43(53.09%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Grade</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">25</td>
<td valign="middle" align="left">11(13.75%)</td>
<td valign="middle" align="left">14(17.28%)</td>
<td valign="middle" align="left">0.4424</td>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">89</td>
<td valign="middle" align="left">48(60.00%)</td>
<td valign="middle" align="left">41(50.62%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">46</td>
<td valign="middle" align="left">20(25.00%)</td>
<td valign="middle" align="left">26(32.10%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">1(1.25%)</td>
<td valign="middle" align="left">0(0%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Stage</td>
<td valign="middle" align="left">I</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">10(12.50%)</td>
<td valign="middle" align="left">7(8.64%)</td>
<td valign="middle" align="left">0.6011</td>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">II</td>
<td valign="middle" align="left">137</td>
<td valign="middle" align="left">68(85.00%)</td>
<td valign="middle" align="left">69(85.19%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">III</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">1(1.25%)</td>
<td valign="middle" align="left">2(2.47%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">IV</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">1(1.25%)</td>
<td valign="middle" align="left">3(3.70%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">T staging</td>
<td valign="middle" align="left">T<sub>1</sub></td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">5(6.25%)</td>
<td valign="middle" align="left">1(1.23%)</td>
<td valign="middle" align="left">0.3240</td>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">T<sub>2</sub></td>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">8(10.00%)</td>
<td valign="middle" align="left">11(13.58%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">T<sub>3</sub></td>
<td valign="middle" align="left">133</td>
<td valign="middle" align="left">66(82.50%)</td>
<td valign="middle" align="left">67(82.72%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">T<sub>4</sub></td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">1(1.25%)</td>
<td valign="middle" align="left">2(2.47%)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">N staging</td>
<td valign="middle" align="left">N<sub>0</sub></td>
<td valign="middle" align="left">46</td>
<td valign="middle" align="left">24(30.00%)</td>
<td valign="middle" align="left">22(27.16%)</td>
<td valign="middle" align="left">0.8225</td>
</tr>
<tr>
<td valign="middle" align="left"/>
<td valign="middle" align="left">N<sub>1</sub></td>
<td valign="middle" align="left">115</td>
<td valign="middle" align="left">56(70.00%)</td>
<td valign="middle" align="left">59(72.84%)</td>
<td valign="middle" align="left"/>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Correlation analysis of model lncRNAs. <bold>(A)</bold> The optimal model combinations established by 5-lncRNAs through multivariate COX analysis. <bold>(B)</bold> Heatmap of target genes significantly associated with model lncRNAs. Indicating that (*, **, and *** represent p-values less than 0.05, 0.01, and 0.001, respectively). <bold>(C)</bold> Expression levels of model lncRNAs in normal and tumor samples. <bold>(D)</bold> Expression levels of model lncRNAs in risk subgroups.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g003.tif">
<alt-text content-type="machine-generated">Panel A features a forest plot depicting hazard ratios of five genetic markers, each represented with corresponding p-values and confidence intervals. Panel B is a heatmap showing the correlation of multiple genes across the same five genetic markers, with significance levels indicated. Panel C displays box plots comparing gene expression in normal and tumor tissues for the markers, highlighting statistical significance. Panel D presents box plots comparing gene expression in high versus low expression groups, also indicating statistical significance.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_2">
<title>Establishment and expression differential analysis of model lncRNA</title>
<p>The correlation analysis based on the model lncRNAs and differently expressed genes show that the model lncRNAs are related to many co-related genes in LLPS and TMU (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>). Additionally, researchers assess the expression differences of model lncRNAs between tumor and normal samples, as well as within the subgroups of high-risk and low-risk (<xref ref-type="fig" rid="f3"><bold>Figures&#xa0;3C, D</bold></xref>). The results indicate significant differences in the expression of model lncRNAs among samples. Furthermore, the results of model RNA are consistent with the multivariate COX result, with <italic>AL157392.3</italic> and <italic>BX284668.2</italic> as low-risk genes, while the other model lncRNAs are high-risk genes.</p>
</sec>
<sec id="s3_3">
<title>Internal dataset survival analysis</title>
<p>The analysis of risk subgroups reveals significant differences in survival outcomes in both the training and validation cohorts (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 4</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>5</bold></xref>). Specifically, the prognosis for the low-risk subgroup is found to be significantly longer than that for the high-risk subgroup (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4A, B</bold></xref>). In both cohorts, the assessment of risk status indicates that the number of patients deaths clearly increases with the risk scores (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4C, D</bold></xref>). The area under the time-dependent ROC curve (AUC) for both datasets surpass 0.66, effectively demonstrating the prediction capability of model lncRNAs (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4E, F</bold></xref>). Furthermore, ROC curves for clinical characteristics indicate that the risk scores is superior to other clinical characteristics as an indicator of prognosis (AUC&#xa0;&gt;&#xa0;0.7) (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4G, H</bold></xref>). To further evaluate the predictive performance of the model, this study assesses the survival time in risk subgroups across various clinical categories (age, sex, grade, and stage, etc). The results highlight significant differences between the low-risk and high-risk subgroups in most clinical categories, thereby further confirming the predictive accuracy of the model lncRNAs (<xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5A&#x2013;L</bold></xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Survival analysis of internal cohort samples. Survival curves for training cohort and validation cohort samples <bold>(A, B)</bold>; Distribution of survival status for training cohort and validation cohort <bold>(C, D)</bold>. The ROC curve distribution for training cohort and validation cohort samples <bold>(E, F)</bold>. The ROC curve distribution for clinical characteristics of training cohort and validation cohort <bold>(G, H)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g004.tif">
<alt-text content-type="machine-generated">Two panels labeled A and B show Kaplan-Meier survival curves comparing high and low-risk groups, with corresponding survival probabilities and p-values of 0.015 and 0.002. Panels C and D display scatter plots of patient survival status against risk scores, indicating survival and death. Panels E and F feature ROC curves with AUC values over one, two, and three years. Panels G and H compare multiple risk factors using ROC curves, with different AUC values for risk, age, gender, grade, stage, T stage, and N stage.</alt-text>
</graphic></fig>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Survival analysis curves for different clinical groups. Risk subgroup survival curves constructed based on clinical characteristics such as patient age <bold>(A, B)</bold>, gender <bold>(C, D)</bold>, tumor stage <bold>(E, F)</bold>, tumor grade <bold>(G, H)</bold>, T staging <bold>(I, J)</bold>, and N staging <bold>(K, L)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g005.tif">
<alt-text content-type="machine-generated">Kaplan-Meier survival curves for different patient groups showing survival probability over time. Subgroups are based on factors like age, gender, tumor stage, and grade. Each plot contrasts high and low-risk groups, with shaded areas indicating confidence intervals. P-values are displayed to indicate statistical significance. Individual plots are labeled from A to L, each with respective patient counts and survival probability over specific timeframes.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_4">
<title>External database validation</title>
<p>This study further analyzes the differences in risk subgroups among samples from the TCGA and ICGC databases (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 6</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>7</bold></xref>). Survival curves indicate that the high-risk subgroup has a shorter survival time compared to the low-risk subgroup (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6A, B</bold></xref>). Additionally, the assessment of survival status clearly demonstrates that there are fewer patients surviving in the high-risk subgroup (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6C, D</bold></xref>). The AUCs based on samples from both databases are basically greater than 0.6 (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6E, F</bold></xref>). While the time-dependent ROC curve within the ICGC dataset shows the lowest value of 0.597 during the first year, it is noteworthy that the predictive accuracy of the model exhibits an overall upward trend over time. Moreover, the AUC for clinical characteristics based on samples from both datasets exceeds 0.68, further confirming the predictive efficacy of the model lncRNAs (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6G, H</bold></xref>). Through verification analysis across different databases, this study evaluates the survival prediction capability of the model lncRNAs from multiple perspectives.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Survival analysis of samples from different databases. Survival curves of samples from TCGA and ICGC database <bold>(A, B)</bold>; Distribution of survival status for samples from TCGA and ICGC database <bold>(C, D)</bold>. ROC curve distribution for samples from TCGA and ICGC database <bold>(E, F)</bold>. ROC curve distribution of clinical characteristics for samples from TCGA and ICGC database <bold>(G, H)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g006.tif">
<alt-text content-type="machine-generated">A) Kaplan-Meier survival curve comparing high and low-risk groups over eight years, showing significant survival difference with p&lt;0.001. B) Similar curve for a smaller group over twelve years with p=0.012. C) Scatter plot of patient survival status and risk scores, indicating death and survival. D) Similar scatter plot for a smaller cohort. E) ROC curve for one to three years with AUC values 0.708, 0.683, and 0.716. F) ROC curve with lower AUC values of 0.597, 0.606, and 0.682. G) Comparison of risk factors with AUC values showing risk has the highest AUC of 0.716. H) Another ROC curve comparison with risk AUC of 0.682.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_5">
<title>Assessment of clinical features of model lncRNAs</title>
<p>To further validate the predictive efficacy of the model lncRNAs for prognosis, this study conducts univariate and multivariate COX regression analyses employing clinical characteristics from samples in the TCGA and ICGC datasets. Both univariate and multivariate COX analyses provide consistent results, indicating that the risk score is significantly associated with patient prognosis (<xref ref-type="fig" rid="f7"><bold>Figures&#xa0;7A&#x2013;D</bold></xref>). This demonstrates that the risk score can serve as an independent risk factor for clinical prognosis assessment, thereby further highlighting the stability of the model lncRNAs in evaluating prognostic efficacy. Additionally, the analysis indicates that tumor stage in ICGC dataset and tumor N staging in TCGA dataset also serve as independent factors.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Assessment of clinical characteristics from samples in different databases. Univariate COX regression analysis of clinical characteristics from samples in the TCGA and ICGC database <bold>(A, B)</bold>; multivariate COX regression analysis of clinical characteristics from samples in the TCGA and ICGC database <bold>(C, D)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g007.tif">
<alt-text content-type="machine-generated">Four panels, A to D, show forest plots of hazard ratios for various factors with their p-values. Panel A and C include factors like age, gender, grade, stage, T stage, N stage, and risk score, while Panels B and D include age, gender, grade, stage, and risk score. Hazard ratios vary by color-coded squares with horizontal lines indicating confidence intervals. Each panel's hazard ratios demonstrate statistical significance at different p-values for the respective variables.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_6">
<title>Mutation differences in risk subgroups</title>
<p>To further compare the differences between the risk subgroups, this study analyzes mutation data of the samples (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 8</bold></xref>). Researchers obtain TMB values for the samples from the TCGA database. The analysis indicates a statistically significant difference in TMB values between the two risk subgroups, demonstrating that mutations vary between them (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8A</bold></xref>). Additionally, the correlation analysis result demonstrates a significant positive correlation between risk scores and TMB values (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8B</bold></xref>). Specifically, this analysis shows that as the risk score increases, the TMB value also rises significantly. Furthermore, survival analysis results reveal clear differences in survival time in the subgroups (<xref ref-type="fig" rid="f8"><bold>Figures&#xa0;8C, D</bold></xref>). This finding further highlights the sensitivity and stability of risk genes in predicting the prognosis status of the samples.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Survival analysis of risk subgroups associated with mutation data. <bold>(A)</bold> Comparison of TMB differences in risk subgroups; <bold>(B)</bold> Correlation analysis between risk scores and TMB value. <bold>(C)</bold> Survival analysis curve for mutation subgroups. <bold>(D)</bold> Survival analysis curves for samples in the mutation and risk subgroup.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g008.tif">
<alt-text content-type="machine-generated">Chart A shows a box plot comparing tumor mutation burden between low-risk and high-risk groups, significant with P&lt;0.001. Chart B is a scatter plot with a positive correlation between tumor mutation burden and risk score, R=0.36, P&lt;0.01. Chart C presents Kaplan-Meier survival curves for high and low tumor mutation burden groups, not significant with P=0.26. Chart D displays Kaplan-Meier curves for combinations of tumor mutation burden and risk, significant with P=0.0014. Patient count tables are provided below charts C and D.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_7">
<title>qPCR validation of model lncRNAs expression</title>
<p>The study analyzes the expression levels of model lncRNAs among different cell lines (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Data Sheet 9</bold></xref>). Specifically, the gene expression levels of the HPDE normal pancreatic ductal tissue cell line are selected as a reference. The protective genes <italic>AL157392.3</italic> and <italic>BX284668.2</italic> demonstrate significantly higher expression levels in the HPDE cell line compared to three other tumor cell lines (<xref ref-type="fig" rid="f9"><bold>Figures&#xa0;9A, B</bold></xref>). This result is consistent with the results of the previous analysis. Furthermore, the high risk genes (<italic>FAM83A-AS1</italic>, <italic>LINC02257</italic>, and <italic>TMEM105</italic>) also exhibit higher expression levels in the three tumor cell lines (<xref ref-type="fig" rid="f9"><bold>Figures&#xa0;9C&#x2013;E</bold></xref>). In summary, the experimental results from qPCR are consistent with database analyses, which further confirms the accuracy and stability of the model lncRNAs at the biological level.</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>The model lncRNA expression levels in different pancreatic cell lines. The expression of model lncRNA AL157392.3 <bold>(A)</bold>, BX284668.2 <bold>(B)</bold>, FAM83A-AS1 <bold>(C)</bold>, LINC02257 <bold>(D)</bold>, and TMEM105 <bold>(E)</bold> in different pancreatic cell lines.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1753321-g009.tif">
<alt-text content-type="machine-generated">Bar graphs labeled A to E compare the expression levels of five genes across four cell lines: HPDE, PANC-1, ASPC-1, and MIA.   Graph A shows AL157392.3 with HPDE highest, P-values all less than 0.0001.   Graph B shows BX284668.2 with similar results.   Graph C shows FAM83A-AS1 with PANC-1 highest and varying P-values.   Graph D shows LINC02257 with MIA highest.   Graph E shows TMEM105 with PANC-1 and MIA highest, multiple P-values less than 0.0001.   All graphs show statistically significant differences.</alt-text>
</graphic></fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Previous studies have shown that LLPS has a significant impact on the formation and regulation of lncRNA, and there is a mutual relationship between TME and LLPS (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). Additionally, the regulatory role of lncRNAs in various cancers has been well confirmed (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Based on these insights, this study focuses on lncRNAs as the research subject and centers on the TME to investigate associations with LLPS to evaluate their potential for predicting prognosis in PC. To ensure the validity of our results, samples with OS of fewer than 30 days are excluded from the analysis (may result from complications such as infections or surgical issues). Moreover, this study employs a broad, integrative gene-set approach, rather than restricting analysis to a single biological process or pathway, to minimize missing potential lncRNAs. GeneCards website is used as the primary source of theme genes, relying on its curated literature evidence and comprehensive integrated gene information to enable precise screening and enhance reproducibility.</p>
<p>This study employs a combined analysis of COX regression and LASSO regression to select an ideal lncRNA combination. Based on the analysis results, the optimal combination is established, which includes six lncRNAs: <italic>AL157392.3</italic>, <italic>BX284668.2</italic>, <italic>FAM83A-AS1</italic>, <italic>LINC02257</italic>, and <italic>TMEM105</italic>. Notably, <italic>AL157392.3</italic> and <italic>BX284668.2</italic> in this combination act as protective genes, and their high expression is beneficial for patient prognosis. Furthermore, the validation of results from risk subgroup survival analyses across multiple databases confirms the effectiveness of this model. However, we observe no statistically significant differences in the Kaplan-Meier survival curves for clinical subgroups in the stage <sub>III-IV</sub> group. This lack of significance may arise from the limited sample size in this subgroup (<xref ref-type="bibr" rid="B33">33</xref>). We also note that the AUC value for the first year in the ICGC cohort is 0.597, which is below 0.60. It is that this situation is influenced by the weaker early signals to some extent, given the evident increased trend in performance, with AUC values of 0.606 and 0.682 in the second and third years, respectively. Additionally, it is worth that clinical cox regression analysis and clinical characteristics ROC curves for risk subgroups also indicate that the model lncRNAs can serve as independent risk factors for patient prognosis. If sufficient samples become available in the future, the research team will further validate the results. Additionally, the analysis related to TMB values indicates that the differences in survival times among samples within the independent mutation subgroup are not statistically significant. This implies that variations in TMB values have no significant impact on the survival time of these samples. However, the combined analysis of mutation subgroups with risk subgroups reveals significant statistical differences, further highlighting the validity and accuracy of the model lncRNAs. Furthermore, the expression levels of the model lncRNAs across the four cell line groups are consistent with analysis results, providing biological evidence that supports the reliability of the results. The lncRNAs <italic>AL157392.3</italic>, <italic>FAM83A-AS1</italic>, <italic>LINC02257</italic>, and <italic>TMEM105</italic> have been previously shown to have a positive correlation with the progression of various cancers, which aligns with the results of this study (<xref ref-type="bibr" rid="B34">34</xref>&#x2013;<xref ref-type="bibr" rid="B38">38</xref>). Among them, <italic>FAM83A-AS1</italic> has been demonstrated to play a regulatory role in TME-related signaling pathways such as PI3K, Hippo, and ERK (<xref ref-type="bibr" rid="B36">36</xref>). <italic>LINC02257</italic> has also been shown to influence the expression of <italic>SERPINE1</italic>, which participates in multiple TME signaling pathways, including MAPK and TGF signaling pathways (<xref ref-type="bibr" rid="B37">37</xref>). Additionally, In NPInter database (version 5.0), the protein partners of <italic>LINC02257</italic>, <italic>BX284668.2</italic>, and <italic>FAM83A-AS1</italic> are DCP1, EWSR1, and hnRNPA1, respectively, all of which are regulators implicated in LLPS processes. This case further indicates the potential of the model lncRNAs and provides a reference for subsequent research and exploration.</p>
<sec id="s4_1">
<title>Limitation</title>
<p>It is worth noting that, although the study validates the effectiveness of model lncRNAs from various angles, there are still several limitations inherent in the research. First, it should be noted that this study focuses on correlation and exploratory analyses, and qPCR is used to corroborate the expression-level findings. Biological mechanisms are not explored in this study. Undeniably, this study is retrospective in nature, which means that its results may be influenced by the intrinsic design of this research method (<xref ref-type="bibr" rid="B39">39</xref>&#x2013;<xref ref-type="bibr" rid="B41">41</xref>). Additionally, It is also worth noting that the present dataset lacks data on resectability status and postoperative adjuvant modalities, such as radiotherapy and chemotherapy, which will influence the performance of the model to some extent. To enhance the evaluation of model lncRNAs performance, researchers attempt to include more samples and data; however, corresponding lncRNAs expression information have not yet been obtained from gene matrices in existing databases. This is also the next direction for the research team, which will involve collecting more clinical samples and supplementary data to further explore and validate the risk signature. In summary, this study explores the association between the TME and LLPS-related gene sets to construct an lncRNA-based prognostic model for PC. The lncRNAs identified from preliminary analyses show potential as predictors of prognosis for PC patients.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>In conclusion, through multi-database analysis, this study explores the associations between the TME and LLPS-related gene sets to establish a lncRNA-based, potentially independent prognostic factor for PC.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Material</bold></xref>.</p></sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>YQW: Funding acquisition, Methodology, Visualization, Writing &#x2013; original draft, Software. XS: Methodology, Software, Writing &#x2013; original draft, Visualization. CD: Investigation, Methodology, Writing &#x2013; review &amp; editing, Data curation, Formal Analysis. YFW: Formal Analysis, Writing &#x2013; review &amp; editing, Methodology, Data curation, Investigation. ZL: Formal Analysis, Methodology, Data curation, Investigation, Writing &#x2013; review &amp; editing. CZ: Methodology, Validation, Conceptualization, Writing &#x2013; review &amp; editing, Investigation, Formal Analysis. HY: Formal Analysis, Conceptualization, Investigation, Writing &#x2013; review &amp; editing, Methodology, Validation. HH: Project administration, Validation, Supervision, Methodology, Writing &#x2013; review &amp; editing.</p></sec>
<ack>
<title>Acknowledgments</title>
<p>Gratitude is extended to the UCSC platform for providing the public data cohorts from TCGA and ICGC; to GenCards and NCBI for their valuable search engines; and to all authors for their careful review and constructive feedback on this manuscript.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2026.1753321/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2026.1753321/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="DataSheet1.xlsx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet2.xlsx" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet3.xlsx" id="SM3" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet4.xlsx" id="SM4" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet5.xlsx" id="SM5" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet6.xlsx" id="SM6" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet7.xlsx" id="SM7" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet8.xlsx" id="SM8" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="DataSheet9.xlsx" id="SM9" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bray</surname> <given-names>F</given-names></name>
<name><surname>Laversanne</surname> <given-names>M</given-names></name>
<name><surname>Sung</surname> <given-names>H</given-names></name>
<name><surname>Ferlay</surname> <given-names>J</given-names></name>
<name><surname>Siegel</surname> <given-names>RL</given-names></name>
<name><surname>Soerjomataram</surname> <given-names>I</given-names></name>
<etal/>
</person-group>. 
<article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA: Cancer J For Clin</source>. (<year>2024</year>) <volume>74</volume>:<page-range>229&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21834</pub-id>, PMID: <pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rahib</surname> <given-names>L</given-names></name>
<name><surname>Wehner</surname> <given-names>MR</given-names></name>
<name><surname>Matrisian</surname> <given-names>LM</given-names></name>
<name><surname>Nead</surname> <given-names>KT</given-names></name>
</person-group>. 
<article-title>Estimated projection of US cancer incidence and death to 2040</article-title>. <source>JAMA Netw Open</source>. (<year>2021</year>) <volume>4</volume>:<fpage>e214708</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.4708</pub-id>, PMID: <pub-id pub-id-type="pmid">33825840</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>S</given-names></name>
<name><surname>Zheng</surname> <given-names>R</given-names></name>
<name><surname>Li</surname> <given-names>J</given-names></name>
<name><surname>Zeng</surname> <given-names>H</given-names></name>
<name><surname>Li</surname> <given-names>L</given-names></name>
<name><surname>Chen</surname> <given-names>R</given-names></name>
<etal/>
</person-group>. 
<article-title>Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN</article-title>. <source>Lancet Gastroenterol Hepatol</source>. (<year>2024</year>) <volume>9</volume>:<page-range>229&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2468-1253(23)00366-7</pub-id>, PMID: <pub-id pub-id-type="pmid">38185129</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Siegel</surname> <given-names>RL</given-names></name>
<name><surname>Giaquinto</surname> <given-names>AN</given-names></name>
<name><surname>Jemal</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Cancer statistics, 2024</article-title>. <source>CA: Cancer J For Clin</source>. (<year>2024</year>) <volume>74</volume>:<fpage>12</fpage>&#x2013;<lpage>49</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21820</pub-id>, PMID: <pub-id pub-id-type="pmid">38230766</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mackay</surname> <given-names>TM</given-names></name>
<name><surname>Latenstein</surname> <given-names>AEJ</given-names></name>
<name><surname>Augustinus</surname> <given-names>S</given-names></name>
<name><surname>van der Geest</surname> <given-names>LG</given-names></name>
<name><surname>Bogte</surname> <given-names>A</given-names></name>
<name><surname>Bonsing</surname> <given-names>BA</given-names></name>
<etal/>
</person-group>. 
<article-title>Implementation of best practices in pancreatic cancer care in the Netherlands: A stepped-wedge randomized clinical trial</article-title>. <source>JAMA Surg</source>. (<year>2024</year>) <volume>159</volume>:<page-range>429&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamasurg.2023.7872</pub-id>, PMID: <pub-id pub-id-type="pmid">38353966</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Klein</surname> <given-names>AP</given-names></name>
</person-group>. 
<article-title>Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors</article-title>. <source>Nat Rev Gastroenterol Hepatology</source>. (<year>2021</year>) <volume>18</volume>:<fpage>493</fpage>&#x2013;<lpage>502</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41575-021-00457-x</pub-id>, PMID: <pub-id pub-id-type="pmid">34002083</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname> <given-names>J</given-names></name>
<name><surname>Lok</surname> <given-names>V</given-names></name>
<name><surname>Ngai</surname> <given-names>CH</given-names></name>
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<name><surname>Yuan</surname> <given-names>J</given-names></name>
<name><surname>Lao</surname> <given-names>XQ</given-names></name>
<etal/>
</person-group>. 
<article-title>Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer</article-title>. <source>Gastroenterology</source>. (<year>2021</year>) <volume>160</volume>:<page-range>744&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1053/j.gastro.2020.10.007</pub-id>, PMID: <pub-id pub-id-type="pmid">33058868</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nojima</surname> <given-names>T</given-names></name>
<name><surname>Proudfoot</surname> <given-names>NJ</given-names></name>
</person-group>. 
<article-title>Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2022</year>) <volume>23</volume>:<fpage>389</fpage>&#x2013;<lpage>406</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-021-00447-6</pub-id>, PMID: <pub-id pub-id-type="pmid">35079163</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmad</surname> <given-names>M</given-names></name>
<name><surname>Weiswald</surname> <given-names>L-B</given-names></name>
<name><surname>Poulain</surname> <given-names>L</given-names></name>
<name><surname>Denoyelle</surname> <given-names>C</given-names></name>
<name><surname>Meryet-Figuiere</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Involvement of lncRNAs in cancer cells migration, invasion and metastasis: cytoskeleton and ECM crosstalk</article-title>. <source>J Exp Clin Cancer Res</source>. (<year>2023</year>) <volume>42</volume>:<fpage>173</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13046-023-02741-x</pub-id>, PMID: <pub-id pub-id-type="pmid">37464436</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname> <given-names>Y-T</given-names></name>
<name><surname>Lin</surname> <given-names>J-F</given-names></name>
<name><surname>Li</surname> <given-names>T</given-names></name>
<name><surname>Li</surname> <given-names>J-J</given-names></name>
<name><surname>Xu</surname> <given-names>R-H</given-names></name>
<name><surname>Ju</surname> <given-names>H-Q</given-names></name>
</person-group>. 
<article-title>LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer</article-title>. <source>Cancer Commun (Lond)</source>. (<year>2021</year>) <volume>41</volume>:<page-range>109&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cac2.12108</pub-id>, PMID: <pub-id pub-id-type="pmid">33119215</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hashemi</surname> <given-names>M</given-names></name>
<name><surname>Moosavi</surname> <given-names>MS</given-names></name>
<name><surname>Abed</surname> <given-names>HM</given-names></name>
<name><surname>Dehghani</surname> <given-names>M</given-names></name>
<name><surname>Aalipour</surname> <given-names>M</given-names></name>
<name><surname>Heydari</surname> <given-names>EA</given-names></name>
<etal/>
</person-group>. 
<article-title>Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy</article-title>. <source>Pharmacol Res</source>. (<year>2022</year>) <volume>184</volume>:<elocation-id>106418</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phrs.2022.106418</pub-id>, PMID: <pub-id pub-id-type="pmid">36038043</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McCabe</surname> <given-names>EM</given-names></name>
<name><surname>Rasmussen</surname> <given-names>TP</given-names></name>
</person-group>. 
<article-title>lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions</article-title>. <source>Semin Cancer Biol</source>. (<year>2021</year>) <volume>75</volume>:<fpage>38</fpage>&#x2013;<lpage>48</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.semcancer.2020.12.012</pub-id>, PMID: <pub-id pub-id-type="pmid">33346133</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tao</surname> <given-names>J</given-names></name>
<name><surname>Yang</surname> <given-names>G</given-names></name>
<name><surname>Zhou</surname> <given-names>W</given-names></name>
<name><surname>Qiu</surname> <given-names>J</given-names></name>
<name><surname>Chen</surname> <given-names>G</given-names></name>
<name><surname>Luo</surname> <given-names>W</given-names></name>
<etal/>
</person-group>. 
<article-title>Targeting hypoxic tumor microenvironment in pancreatic cancer</article-title>. <source>J Hematol Oncol</source>. (<year>2021</year>) <volume>14</volume>:<fpage>14</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13045-020-01030-w</pub-id>, PMID: <pub-id pub-id-type="pmid">33436044</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pereira</surname> <given-names>BA</given-names></name>
<name><surname>Vennin</surname> <given-names>C</given-names></name>
<name><surname>Papanicolaou</surname> <given-names>M</given-names></name>
<name><surname>Chambers</surname> <given-names>CR</given-names></name>
<name><surname>Herrmann</surname> <given-names>D</given-names></name>
<name><surname>Morton</surname> <given-names>JP</given-names></name>
<etal/>
</person-group>. 
<article-title>CAF subpopulations: A new reservoir of stromal targets in pancreatic cancer</article-title>. <source>Trends Cancer</source>. (<year>2019</year>) <volume>5</volume>:<page-range>724&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.trecan.2019.09.010</pub-id>, PMID: <pub-id pub-id-type="pmid">31735290</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sempere</surname> <given-names>LF</given-names></name>
<name><surname>Powell</surname> <given-names>K</given-names></name>
<name><surname>Rana</surname> <given-names>J</given-names></name>
<name><surname>Brock</surname> <given-names>AA</given-names></name>
<name><surname>Schmittgen</surname> <given-names>TD</given-names></name>
</person-group>. 
<article-title>Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer</article-title>. <source>Cancer Metastasis Rev</source>. (<year>2021</year>) <volume>40</volume>:<page-range>761&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10555-021-09995-x</pub-id>, PMID: <pub-id pub-id-type="pmid">34591242</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gong</surname> <given-names>Y</given-names></name>
<name><surname>Gong</surname> <given-names>D</given-names></name>
<name><surname>Liu</surname> <given-names>S</given-names></name>
<name><surname>Gong</surname> <given-names>X</given-names></name>
<name><surname>Xiong</surname> <given-names>J</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Deciphering the role of NcRNAs in Pancreatic Cancer immune evasion and drug resistance: a new perspective for targeted therapy</article-title>. <source>Front In Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1480572</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1480572</pub-id>, PMID: <pub-id pub-id-type="pmid">39555076</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shi</surname> <given-names>M</given-names></name>
<name><surname>Zhang</surname> <given-names>R</given-names></name>
<name><surname>Lyu</surname> <given-names>H</given-names></name>
<name><surname>Xiao</surname> <given-names>S</given-names></name>
<name><surname>Guo</surname> <given-names>D</given-names></name>
<name><surname>Zhang</surname> <given-names>Q</given-names></name>
<etal/>
</person-group>. 
<article-title>Long non-coding RNAs: Emerging regulators of invasion and metastasis in pancreatic cancer</article-title>. <source>J Adv Res</source>. (<year>2025</year>) <volume>78</volume>:<page-range>285&#x2013;306</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jare.2025.02.001</pub-id>, PMID: <pub-id pub-id-type="pmid">39933650</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tong</surname> <given-names>X</given-names></name>
<name><surname>Tang</surname> <given-names>R</given-names></name>
<name><surname>Xu</surname> <given-names>J</given-names></name>
<name><surname>Wang</surname> <given-names>W</given-names></name>
<name><surname>Zhao</surname> <given-names>Y</given-names></name>
<name><surname>Yu</surname> <given-names>X</given-names></name>
<etal/>
</person-group>. 
<article-title>Liquid-liquid phase separation in tumor biology</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2022</year>) <volume>7</volume>:<fpage>221</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-022-01076-x</pub-id>, PMID: <pub-id pub-id-type="pmid">35803926</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname> <given-names>Q</given-names></name>
<name><surname>Shi</surname> <given-names>X</given-names></name>
<name><surname>Wang</surname> <given-names>X</given-names></name>
</person-group>. 
<article-title>RNA and liquid-liquid phase separation</article-title>. <source>Noncoding RNA Res</source>. (<year>2021</year>) <volume>6</volume>:<page-range>92&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ncrna.2021.04.003</pub-id>, PMID: <pub-id pub-id-type="pmid">33997539</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>W</given-names></name>
<name><surname>Li</surname> <given-names>Y</given-names></name>
<name><surname>Zhou</surname> <given-names>Q</given-names></name>
<name><surname>Peng</surname> <given-names>W</given-names></name>
<name><surname>Cao</surname> <given-names>M</given-names></name>
<name><surname>Zhao</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>The cancer-associated fibroblast facilitates YAP liquid-liquid phase separation to promote cancer cell stemness in HCC</article-title>. <source>Cell Commun Signal</source>. (<year>2025</year>) <volume>23</volume>:<fpage>238</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12964-025-02256-2</pub-id>, PMID: <pub-id pub-id-type="pmid">40413530</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Somasundaram</surname> <given-names>K</given-names></name>
<name><surname>Gupta</surname> <given-names>B</given-names></name>
<name><surname>Jain</surname> <given-names>N</given-names></name>
<name><surname>Jana</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>LncRNAs divide and rule: The master regulators of phase separation</article-title>. <source>Front Genet</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>930792</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2022.930792</pub-id>, PMID: <pub-id pub-id-type="pmid">36035193</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roden</surname> <given-names>C</given-names></name>
<name><surname>Gladfelter</surname> <given-names>AS</given-names></name>
</person-group>. 
<article-title>RNA contributions to the form and function of biomolecular condensates</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>183&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-020-0264-6</pub-id>, PMID: <pub-id pub-id-type="pmid">32632317</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mehta</surname> <given-names>S</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Liquid-liquid phase separation drives cellular function and dysfunction in cancer</article-title>. <source>Nat Rev Cancer</source>. (<year>2022</year>) <volume>22</volume>:<page-range>239&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41568-022-00444-7</pub-id>, PMID: <pub-id pub-id-type="pmid">35149762</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname> <given-names>L-W</given-names></name>
<name><surname>Liu</surname> <given-names>C-C</given-names></name>
<name><surname>Yu</surname> <given-names>K-D</given-names></name>
</person-group>. 
<article-title>Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer</article-title>. <source>J Hematol Oncol</source>. (<year>2023</year>) <volume>16</volume>:<fpage>123</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13045-023-01522-5</pub-id>, PMID: <pub-id pub-id-type="pmid">38110976</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<name><surname>Chen</surname> <given-names>L-L</given-names></name>
</person-group>. 
<article-title>Organization and function of paraspeckles</article-title>. <source>Essays Biochem</source>. (<year>2020</year>) <volume>64</volume>:<page-range>875&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/EBC20200010</pub-id>, PMID: <pub-id pub-id-type="pmid">32830222</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>J</given-names></name>
<name><surname>Xie</surname> <given-names>W</given-names></name>
<name><surname>Yang</surname> <given-names>Z</given-names></name>
<name><surname>Zhao</surname> <given-names>M</given-names></name>
<name><surname>Ke</surname> <given-names>T</given-names></name>
<name><surname>Xu</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Identification and characterization of a special type of subnuclear structure: AGGF1-coated paraspeckles</article-title>. <source>FASEB J</source>. (<year>2022</year>) <volume>36</volume>:<fpage>e22366</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1096/fj.202101690RR</pub-id>, PMID: <pub-id pub-id-type="pmid">35608889</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ren</surname> <given-names>J</given-names></name>
<name><surname>Zhang</surname> <given-names>Z</given-names></name>
<name><surname>Zong</surname> <given-names>Z</given-names></name>
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<name><surname>Zhou</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>Emerging implications of phase separation in cancer</article-title>. <source>Adv Sci (Weinh)</source>. (<year>2022</year>) <volume>9</volume>:<fpage>e2202855</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/advs.202202855</pub-id>, PMID: <pub-id pub-id-type="pmid">36117111</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname> <given-names>X</given-names></name>
<name><surname>Zhang</surname> <given-names>M</given-names></name>
<name><surname>Wang</surname> <given-names>D</given-names></name>
</person-group>. 
<article-title>Interplay between posttranslational modifications and liquid&#x2013;liquid phase separation in tumors</article-title>. <source>Cancer Lett</source>. (<year>2024</year>) <volume>584</volume>:<elocation-id>216614</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2024.216614</pub-id>, PMID: <pub-id pub-id-type="pmid">38246226</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nozawa</surname> <given-names>R-S</given-names></name>
<name><surname>Yamamoto</surname> <given-names>T</given-names></name>
<name><surname>Takahashi</surname> <given-names>M</given-names></name>
<name><surname>Tachiwana</surname> <given-names>H</given-names></name>
<name><surname>Maruyama</surname> <given-names>R</given-names></name>
<name><surname>Hirota</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Nuclear microenvironment in cancer: Control through liquid-liquid phase separation</article-title>. <source>Cancer Sci</source>. (<year>2020</year>) <volume>111</volume>:<page-range>3155&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cas.14551</pub-id>, PMID: <pub-id pub-id-type="pmid">32594560</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>Y-T</given-names></name>
<name><surname>Cao</surname> <given-names>L-Y</given-names></name>
<name><surname>Sun</surname> <given-names>Z-J</given-names></name>
</person-group>. 
<article-title>The emerging roles of liquid-liquid phase separation in tumor immunity</article-title>. <source>Int Immunopharmacol</source>. (<year>2024</year>) <volume>143</volume>:<elocation-id>113212</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2024.113212</pub-id>, PMID: <pub-id pub-id-type="pmid">39353387</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bin</surname> <given-names>W</given-names></name>
<name><surname>Yuan</surname> <given-names>C</given-names></name>
<name><surname>Qie</surname> <given-names>Y</given-names></name>
<name><surname>Dang</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Long non-coding RNAs and pancreatic cancer: A multifaceted view</article-title>. <source>BioMed Pharmacother</source>. (<year>2023</year>) <volume>167</volume>:<elocation-id>115601</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2023.115601</pub-id>, PMID: <pub-id pub-id-type="pmid">37774671</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ashrafizadeh</surname> <given-names>M</given-names></name>
<name><surname>Rabiee</surname> <given-names>N</given-names></name>
<name><surname>Kumar</surname> <given-names>AP</given-names></name>
<name><surname>Sethi</surname> <given-names>G</given-names></name>
<name><surname>Zarrabi</surname> <given-names>A</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Long noncoding RNAs (lncRNAs) in pancreatic cancer progression</article-title>. <source>Drug Discov Today</source>. (<year>2022</year>) <volume>27</volume>:<page-range>2181&#x2013;98</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.drudis.2022.05.012</pub-id>, PMID: <pub-id pub-id-type="pmid">35589014</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname> <given-names>S</given-names></name>
<name><surname>Shen</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>Avoiding definitive conclusions in meta-analysis of heterogeneous studies with small sample sizes</article-title>. <source>JAMA Otolaryngol Head Neck Surg</source>. (<year>2022</year>) <volume>148</volume>:<page-range>1003&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamaoto.2022.2847</pub-id>, PMID: <pub-id pub-id-type="pmid">36136342</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname> <given-names>K-H</given-names></name>
<name><surname>Huang</surname> <given-names>T-W</given-names></name>
<name><surname>Shih</surname> <given-names>C-M</given-names></name>
<name><surname>Lee</surname> <given-names>Y-T</given-names></name>
<name><surname>Liu</surname> <given-names>A-J</given-names></name>
<name><surname>Chen</surname> <given-names>P-H</given-names></name>
<etal/>
</person-group>. 
<article-title>Glycolysis-associated lncRNAs identify a subgroup of cancer patients with poor prognoses and a high-infiltration immune microenvironment</article-title>. <source>BMC Med</source>. (<year>2021</year>) <volume>19</volume>:<fpage>59</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12916-021-01925-6</pub-id>, PMID: <pub-id pub-id-type="pmid">33627136</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>H</given-names></name>
<name><surname>Ding</surname> <given-names>Y</given-names></name>
<name><surname>Zhu</surname> <given-names>Q</given-names></name>
<name><surname>Yu</surname> <given-names>Z</given-names></name>
<name><surname>Wang</surname> <given-names>Q</given-names></name>
<name><surname>Gong</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>LncRNA FAM83A-AS1 promotes epithelial-mesenchymal transition of pancreatic cancer cells via Hippo pathway</article-title>. <source>Cell Cycle</source>. (<year>2023</year>) <volume>22</volume>:<page-range>1514&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15384101.2023.2216507</pub-id>, PMID: <pub-id pub-id-type="pmid">37245082</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>C</given-names></name>
<name><surname>Li</surname> <given-names>X</given-names></name>
<name><surname>Zhang</surname> <given-names>R</given-names></name>
<etal/>
</person-group>. 
<article-title>Sense and anti-sense: Role of FAM83A and FAM83A-AS1 in Wnt, EGFR, PI3K, EMT pathways and tumor progression</article-title>. <source>BioMed Pharmacother</source>. (<year>2024</year>) <volume>173</volume>:<elocation-id>116372</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.116372</pub-id>, PMID: <pub-id pub-id-type="pmid">38432129</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname> <given-names>M-S</given-names></name>
<name><surname>Jeong</surname> <given-names>SD</given-names></name>
<name><surname>Shin</surname> <given-names>CH</given-names></name>
<name><surname>Cha</surname> <given-names>S</given-names></name>
<name><surname>Yu</surname> <given-names>A</given-names></name>
<name><surname>Kim</surname> <given-names>EJ</given-names></name>
<etal/>
</person-group>. 
<article-title>LINC02257 regulates Malignant phenotypes of colorectal cancer via interacting with miR-1273g-3p and YB1</article-title>. <source>Cell Death Dis</source>. (<year>2024</year>) <volume>15</volume>:<fpage>895</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-024-07259-4</pub-id>, PMID: <pub-id pub-id-type="pmid">39695079</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yin</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>Y</given-names></name>
<name><surname>Yao</surname> <given-names>H</given-names></name>
<name><surname>Yu</surname> <given-names>F</given-names></name>
<name><surname>Jia</surname> <given-names>Q</given-names></name>
<name><surname>Hu</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>TMEM105 modulates disulfidptosis and tumor growth in pancreatic cancer via the &#x3b2;-catenin-c-MYC-GLUT1 axis</article-title>. <source>Int J Biol Sci</source>. (<year>2025</year>) <volume>21</volume>:<page-range>1932&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/ijbs.104598</pub-id>, PMID: <pub-id pub-id-type="pmid">40083702</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ramgopal</surname> <given-names>S</given-names></name>
<name><surname>Benedetti</surname> <given-names>J</given-names></name>
<name><surname>Cotter</surname> <given-names>JM</given-names></name>
</person-group>. 
<article-title>Performing a multicenter retrospective study</article-title>. <source>Hosp Pediatr</source>. (<year>2025</year>) <volume>15</volume>:<page-range>e77&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1542/hpeds.2024-008020</pub-id>, PMID: <pub-id pub-id-type="pmid">39746377</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Greenland</surname> <given-names>S</given-names></name>
<name><surname>Senn</surname> <given-names>SJ</given-names></name>
<name><surname>Rothman</surname> <given-names>KJ</given-names></name>
<name><surname>Carlin</surname> <given-names>JB</given-names></name>
<name><surname>Poole</surname> <given-names>C</given-names></name>
<name><surname>Goodman</surname> <given-names>SN</given-names></name>
<etal/>
</person-group>. 
<article-title>Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations</article-title>. <source>Eur J Epidemiol</source>. (<year>2016</year>) <volume>31</volume>:<page-range>337&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10654-016-0149-3</pub-id>, PMID: <pub-id pub-id-type="pmid">27209009</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaji</surname> <given-names>AH</given-names></name>
<name><surname>Schriger</surname> <given-names>D</given-names></name>
<name><surname>Green</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Looking through the retrospectoscope: reducing bias in emergency medicine chart review studies</article-title>. <source>Ann Emerg Med</source>. (<year>2014</year>) <volume>64</volume>:<page-range>292&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.annemergmed.2014.03.025</pub-id>, PMID: <pub-id pub-id-type="pmid">24746846</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1703913">Hao Liu</ext-link>, Houston Methodist Hospital, United States</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3269472">Lei Qi</ext-link>, University of California, Los Angeles, United States</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3316125">Zhiting Tang</ext-link>, University of Missouri, United States</p></fn>
</fn-group>
</back>
</article>